Rallybio Sets Record Date and Reveals CFO Transition in Latest Avenzo Merger Amendment
RLYB has more than doubled off its 52-week low of $3.67 on light trading volume (0.3× avg).
Summary
Rallybio's latest S-4 amendment sets the shareholder meeting record date and reveals that CFO Jonathan Lieber has moved to part-time status, with Avenzo's Herb Cross already hired as his successor.
Key Events · M&A and Partnerships · RLYB
-
Record Date Set for Merger Vote
The Rallybio annual meeting record date is September 11, 2026, with 5,312,584 shares of common stock outstanding and entitled to vote on the Avenzo reverse merger proposals.
-
CFO Transitions to Part-Time
CFO Jonathan Lieber moved to part-time status effective September 15, 2026, with a reduced base salary of $420,000 and no annual bonus. His employment will terminate upon the merger closing.
-
Avenzo Hires New CFO
Avenzo entered into an employment agreement with Herb Cross in September 2026, with a $520,000 annual base salary, a target bonus of up to 40%, and an anticipated option grant for 3,155,190 shares of Avenzo Common Stock.
-
Merger Timeline Advances
The merger is anticipated to close in the fourth quarter of 2026, with the combined company expected to trade on Nasdaq under the symbol 'AVZO' following the reverse stock split and name change.
Analysis · RLYB · Life Sciences
Amendment No. 3 to the S-4 advances the Avenzo reverse merger toward a shareholder vote by setting the record date of September 11, 2026, with 5,312,584 shares outstanding. More notably, it discloses that CFO Jonathan Lieber has transitioned to part-time status effective September 15, 2026, with a reduced salary and no bonus, and that his employment will terminate upon the merger closing. Avenzo has already lined up his successor, Herb Cross, with a $520,000 base salary and a substantial option grant. The CFO change during a pending reverse merger is a governance signal that the transaction is progressing toward completion, but it also raises questions about continuity in financial leadership during a critical period.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $17.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.7M. The 52-week trading range was $3.67 to $17.57. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.